Sitostenone
CAS No. 1058-61-3
Sitostenone ( —— )
Catalog No. M22863 CAS No. 1058-61-3
Sitostenone has antioxidation activity. Stigmasta-4-en-3-one(Sitostenone) can be used for the treatment of androgen-dependent diseases, especially for the treatment of benign prostatic hyperplasia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 216 | In Stock |
|
10MG | 320 | In Stock |
|
25MG | 529 | In Stock |
|
50MG | 770 | In Stock |
|
100MG | 1062 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSitostenone
-
NoteResearch use only, not for human use.
-
Brief DescriptionSitostenone has antioxidation activity. Stigmasta-4-en-3-one(Sitostenone) can be used for the treatment of androgen-dependent diseases, especially for the treatment of benign prostatic hyperplasia.
-
DescriptionSitostenone has antioxidation activity. Stigmasta-4-en-3-one(Sitostenone) can be used for the treatment of androgen-dependent diseases, especially for the treatment of benign prostatic hyperplasia.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1058-61-3
-
Formula Weight412.7
-
Molecular FormulaC29H48O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCCC(CCC(C)C1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C)C(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Antioxidant and anticancer aporphine alkaloids from the leaves of Nelumbo nucifera Gaertn. cv. Rosa-plena. Molecules. 2014 Nov 3;19(11):17829-38
molnova catalog
related products
-
Ginkgolic acid
Ginkgolic acid C13: exhibits the highest α-glucosidase inhibitory activity.
-
VPC-80051 racemate
VPC-80051 is the first small molecule inhibitor of hnRNP A1 splicing activity by using a computer-aided drug discovery approach.
-
36-Dihydroxyflavone
36-Dihydroxyflavone?suppresses the epithelial-mesenchymal transition in breast cancer cells by inhibiting the Notch signaling pathway.